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AbsTrACT
Pharmacist–patient counselling can benefit patients and 
optimise care, but appropriate training is required. A 
virtual patient (VP) tool to teach pharmacists non-vitamin 
K oral anticoagulant counselling was developed; the VP 
may be used for continuing professional development. 
The objective was to develop and show proof of concept 
of the VP. A cyclic development approach was adopted 
whereby the client, developers and a steering group 
informed VP design, content and aesthetic. This included 
formal and informal evaluation; ethical approval was 
not required. The VP received varied feedback. Positive 
feedback concerned the technology and the high-
standard of animations. Negative elements concerned 
international VP use and differences in practice, also 
technological comments, regarding VP delivery and 
usability on various electronic devices. The VP was 
reported to be ’valuable’ and realistic with high-quality 
animations. The steering group commented on VP’s 
clinical appropriateness, cultural relevance and usability. 
Areas highlighted for improvement were rectified 
during development, including the incorporation of 
printable feedback. European considerations concerned 
differences in culture and practice. The development 
process successfully developed the VP and the proof of 
the concept was demonstrated. This will inform future VP 
development; a large-scale VP evaluation is underway.
InTroduCTIon
When patients commence new medications, they 
require counselling by a health professional which 
can empower patients to adopt positive self-man-
agement, increase satisfaction and optimise care.1 
Pharmacists providing counselling need to be 
trained appropriately; Keele University has devel-
oped a virtual patient (VP) educational tool on 
the topic of non-vitamin K oral anticoagulants 
(NOACs) to treat atrial fibrillation (AF) (https://
www. keelevp. com/ virtual- patient/ newly- diagnosed- 
af- patient) (figure 1).
The VPs uses a clinical decision pathway with 
corresponding visual effects to show an avatar 
responding to the user’s decisions. Personalised 
feedback is provided at the case conclusion to 
enhance counselling ability. The VP was developed 
with Bayer AG and is aimed at European pharma-
cists to improve practice. Many pharmacists are 
required to conduct continuing professional devel-
opment, an anticipated VP purpose.
There are few anticoagulant and AF training 
or resources are available and most focus on facts 
rather than real-life consultations2; no NOAC 
training using VPs has been identified. VPs have 
scarcely been investigated and they can vary 
remarkably in definition and design.3–5 VPs are 
more widely investigated in medicine and with 
students rather than health professionals.6–8 VPs 
have shown high levels of user satisfaction, usability 
and likeability,6 9 as well as improvements in knowl-
edge, confidence and counselling skills, all while 
being fun and engaging.8 10–12 The potential to teach 
qualified healthcare professionals, including phar-
macists, has been highlighted for the future.7 13 This 
research aimed to develop a VP for pharmacists 
who conduct NOAC counselling.
MeThods
The VP was designed specifically around NOAC 
and AF educational needs. This study presents 
the VP development to demonstrate a proof of 
concept; ethical approval was not required. Within 
the tool, the patient presents to their pharmacy 
with a prescription for a NOAC: rivaroxaban. 
The case is intended to be as realistic as possible; 
every detail was considered and designed including 
the patient characteristics, script and the feedback 
provided. Intended learning outcomes were estab-
lished followed by a script and animations.
Due to the intention to use the VP across Europe, 
a steering group of European pharmacists provided 
data for VP development, exploring the VP concept. 
Their brief was to advise on the case to ensure it was 
realistic, clinically accurate and appropriate for use. 
The technology-orientated VP team led a three-way 
cyclical approach14 whereby the development team, 
client and steering group informed development 
and provided feedback. The VP uses computer-gen-
erated animated videos via HTML, CSS and Javas-
cript resource accessing video renders.
The development of the VP was conducted 
through a blend of formal meetings, distance 
evaluation using formal forms and informal email 
feedback. Evaluation forms were a mixture of 
quantitative and qualitative questions. Feedback 
areas consisted of a number of VP elements: 
technological feedback, text (clinical content and 
style), spoken text, pictures/visual effects and 
case feedback. During development, feedback 
was deliberated by the involved parties to inform 
VP design; Bayer AG was regularly updated on 
development.
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resulTs
A steering group evaluated the VP concept; they were from 
different European countries and had a range of experiences. 
They all trialled the VP; some trialled it on multiple types of 
electronic device. The VP received good feedback when the 
reviewers were asked if they liked the case, with 60% (n=5, 
response rate, n=6) of responses indicating a neutral or better 
answer. One response was negative; however, this individual 
trialled the VP on multiple devices. When they used a laptop/
computer and smartphone rather than a tablet, their response 
improved from ‘No, I don’t feel comfortable using it’ to ‘Yes, I 
do like it a bit’ and ‘Yes, I do like it very much’, respectively. This 
was controversial as some reviewers favoured the tablet version 
but others the smartphone or laptop versions. Interpretation of 
this is limited by the small numbers. One respondent highlighted 
that they would not undertake training on their phone but would 
choose more ‘traditional methods’.
The VP received many positive comments but, as with a devel-
opment process, elements were highlighted for improvement. 
Many negatives were technological, relating to the device being 
used, but positives included comments on the animations and 
case realism. The VP’s potential for training newly qualified 
pharmacists was highlighted. One reviewer thought that the 
VP was too time intensive for regular use in practice. Similarly, 
multiple reviewers suggested more feedback concerning if what 
they had done within the case was correct or not. Nevertheless, 
the VP was stated to ‘valuable’.
Some reviewers focused on pharmacy practice within one 
country and the implications for this on the VP design, rather 
than considering the VP broadly. For instance, in some coun-
tries including Germany, the use of a consultation room is 
uncommon and these users may not make use of the consultation 
room within the case and thus would receive negative feedback. 
Another cross-cultural consideration concerned whether the 
patient should pay for their medication. Suggested improve-
ments included the option for users to register on the website 
so that progress could be saved and returned to; this was subse-
quently adopted. As was the option to print or save a PDF of 
personalised feedback.
The steering group provided feedback on case iterations; this 
included the patient’s expressions not fitting with script, and this 
was appropriately changed: changes to the virtual environment 
to make the pharmacy size more ambiguous and changes to 
clinical elements of the script, for example, whether Henry’s 
co-medications would impact the case. There was a discussion 
around the use of Xarelto as the drug brand versus rivaroxaban 
as the drug name. Efforts were made to increase VP usability and 
make it ‘user friendly’.
dIsCussIon
Feedback suggested that the reviewers liked the VP concept but 
that delivery on different devices could be improved. Some data 
supported that the smartphone version was more usable than 
the other types, but one reviewer was opposed to using a mobile 
phone for learning. This was anticipated during development 
and the VP was designed to be available on various devices, 
suited to a range of personal preferences. This is in keeping 
with the intention for the VP to be accessible whenever required 
without technological boundaries. After design finalisation, the 
computer and mobile device versions were amended to look and 
function identically. This overcame many negative comments.
Most reviewers responded promisingly towards the concept 
and implications of the VP, provided there were delivery 
Figure 1 The virtual patient programme interface.
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improvements; reviewers were aware that the VP was an early 
iteration in development. Negative comments and technological 
suggestions were considered and the VP was amended as deemed 
appropriate by the development team. Increased user feedback 
was suggested with proposals of incorporating a pass/fail or 
percentage mark. The lack of this was an intentional design 
feature as there is not necessarily a ‘correct answer’ to the VP. 
It was hoped that this would empower participants to reattempt 
the case and explore alternative pathways, as well as to promote 
reflection, in keeping with pedagogy rationales of problem-based 
learning and theories of reflective learning through practice.15 
One reviewer struggled to appreciate that the VP was not to 
teach overt knowledge but to allow an opportunity to practice. 
It was highlighted that the VP may be useful for newly qualified 
pharmacists. This was an intended purpose of the VP, signifying 
that the VP was successfully designed around its brief.
As the VP was European, it was adapted due to differences 
in practice and culture. Regarding the use of a consultation 
room, it was made clear to users that the scenario is an ideal 
environment which includes a consultation room that should be 
made use of where appropriate. A further controversial topic 
concerned medication payment; this was removed from the 
case. In the UK, Henry is entitled to free medication; secondly, 
although payment is required in many countries, there may be 
price changes which could out date the case prematurely and 
finally, considering the main VP purpose was to develop coun-
selling, taking payment was unessential. A similar discussion 
ensued regarding use of the brand and drug names, ultimately 
the use of the drug name (rivaroxaban) was decided on. Many 
other suggestions were incorporated into the VP including the 
option to print or save case feedback. This was added as written 
feedback may allow confirmation of learning and can be used to 
document continuing professional development.
The small number of reviewers was a limitation, this will be 
addressed in a wider study that is evaluating the usefulness, 
implications and integration of the VP, and this is ongoing. The 
respondents were from different countries and so were likely to 
have different opinions, this was purposive to establish views 
and cultural perspectives from multiple outlooks, although from 
individuals.
ConClusIons
The VP met the needs of the client and their application. Devel-
opment was effective, in that a VP was created that is clinically 
accurate, realistic and useful, from the point of view of the 
steering group thus demonstrating proof of the VP concept ready 
for wider evaluation. These findings can inform future VP devel-
opment and encourage the pharmacy profession to consider VPs 
as an alternative educational resource.
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